Diverse pipeline of innovative therapies across a broad range of indications

antibody
Dren Bio has generated a broad and diverse pipeline that encompasses multiple clinical and preclinical programs. Both DR-01 and the Targeted Myeloid Engager and Phagocytosis Platform are wholly owned and were developed by leveraging Dren Bio’s deep expertise in immunology and protein engineering.

1. Press Release: Sanofi completes acquisition of DR-0201 (May 27, 2025)

DR-01 Program (Selective Autoreactive Cell Depletion)

DR-01 is a first-in-class antibody therapeutic designed to selectively deplete terminally differentiated cytotoxic cells such as autoreactive CD8 T cells, which are known to play a pathogenic role in various hematological and autoimmune diseases.

DR-01 is currently being evaluated in large granular lymphocytic leukemia (LGLL) and cytotoxic lymphoma (CTL) patients and is expanding into various autoimmune indications.

DR-0202 Program

Dren Bio’s second platform program, DR-0202, is a first-in-class bispecific antibody that harnesses myeloid cells to selectively deplete cancer cells by targeting a cell surface receptor that is highly expressed in various solid tumors. By leveraging myeloid cells to deplete tumor cells and subsequently cross-present antigens, DR-0202 primes the adaptive immune system to potentially elicit deep and durable responses.

IND-enabling activities are currently underway for DR-0202, with a first-in-human study to be initiated in early 2025.

Undisclosed Programs

Dren Bio’s versatile platform has yielded a deep pipeline of preclinical programs across various therapeutic areas including oncology, immunology, and neurology.